FULC Stock Overview
A clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Fulcrum Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.29 |
| 52 Week High | US$10.13 |
| 52 Week Low | US$2.32 |
| Beta | 2.13 |
| 1 Month Change | 8.94% |
| 3 Month Change | -16.92% |
| 1 Year Change | -53.40% |
| 3 Year Change | -71.04% |
| 5 Year Change | -70.20% |
| Change since IPO | -75.63% |
Recent News & Updates
Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Business And Shares Still Trailing The Industry
Apr 04
There's Reason For Concern Over Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Massive 34% Price Jump
Dec 23We Think Fulcrum Therapeutics (NASDAQ:FULC) Can Easily Afford To Drive Business Growth
Nov 08Recent updates
Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Business And Shares Still Trailing The Industry
Apr 04There's Reason For Concern Over Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Massive 34% Price Jump
Dec 23We Think Fulcrum Therapeutics (NASDAQ:FULC) Can Easily Afford To Drive Business Growth
Nov 08Some Confidence Is Lacking In Fulcrum Therapeutics, Inc. (NASDAQ:FULC) As Shares Slide 62%
Sep 13Fulcrum Therapeutics: Tough Day As Losmapimod FSHD Phase 3 Misses Badly
Sep 12Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?
Jul 12Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
Feb 11We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
Oct 28We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
Jul 11What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today
Nov 17We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
Oct 18Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts
Aug 13Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M
Aug 11Fulcrum Therapeutics says chief medical officer Christopher Morabito to leave
Jul 11Fulcrum begins dosing in late-stage study of losmapimod for rare muscle disorder
Jul 05Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling
Jun 27These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat
May 10Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth
Apr 09Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
Dec 09Fulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry Point
Sep 03Analysts Are Upgrading Fulcrum Therapeutics, Inc. (NASDAQ:FULC) After Its Latest Results
Aug 12Shareholder Returns
| FULC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 25.3% | 8.1% | -0.05% |
| 1Y | -53.4% | -2.2% | 5.7% |
Return vs Industry: FULC underperformed the US Pharmaceuticals industry which returned -8% over the past year.
Return vs Market: FULC underperformed the US Market which returned 4.6% over the past year.
Price Volatility
| FULC volatility | |
|---|---|
| FULC Average Weekly Movement | 9.6% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: FULC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: FULC's weekly volatility (10%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 45 | Alex Sapir | www.fulcrumtx.com |
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond syndrome, and fanconi anemia, as well as novel fetal hemoglobin inducers, fibrotic disorders, and cardiomyopathies which is in preclinical trial.
Fulcrum Therapeutics, Inc. Fundamentals Summary
| FULC fundamental statistics | |
|---|---|
| Market cap | US$165.18m |
| Earnings (TTM) | -US$9.72m |
| Revenue (TTM) | US$80.00m |
2.2x
P/S Ratio-18.3x
P/E RatioIs FULC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FULC income statement (TTM) | |
|---|---|
| Revenue | US$80.00m |
| Cost of Revenue | US$63.39m |
| Gross Profit | US$16.61m |
| Other Expenses | US$26.34m |
| Earnings | -US$9.72m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.18 |
| Gross Margin | 20.77% |
| Net Profit Margin | -12.16% |
| Debt/Equity Ratio | 0% |
How did FULC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/17 15:11 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fulcrum Therapeutics, Inc. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Dae Gon Ha | BTIG |
| Kristen Kluska | Cantor Fitzgerald & Co. |